Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Erlotinib Stories

2012-01-05 07:30:00

WALTHAM, Mass. and TUCSON, Ariz., Jan. 5, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. and Ventana Medical Systems, Inc. announced that the companies have entered into an agreement to develop a companion diagnostic assay to select patients with non-small cell lung cancer (NSCLC) for treatment with erlotinib and Syndax's proprietary lead molecule entinostat. "Syndax is pleased to partner with Ventana, a world leader and innovator of tissue-based diagnostic solutions for patients...

2011-12-16 12:15:00

PORTSMOUTH, N.H., Dec. 16, 2011 /PRNewswire/ -- Novocure, a commercial stage private oncology company, announced today the addition of three former senior OSI Pharmaceuticals executives to its Global Commercialization Team. The Global Commercialization Team is responsible for bringing the company's new tumor treating fields (TTF) cancer therapy to patients worldwide. Peter M. Melnyk has joined Novocure as chief commercial officer responsible for directing the company's global...

2011-11-18 15:19:00

CAMBRIDGE, Mass., Nov. 18, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with erlotinib (Tarceva®), a small molecule directed at the epidermal growth factor receptor (EGFR), in three groups of patients with metastatic non-small cell lung cancer (NSCLC). (Logo: <font size="2"...

2011-11-13 09:00:00

SAN FRANCISCO and WALTHAM, Mass., Nov. 13, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that pharmacodynamic analysis in a subset of patients from ENCORE 301, a placebo-controlled, randomized phase 2 study of exemestane with and without entinostat in postmenopausal estrogen-receptor positive breast cancer patients demonstrates the association of the pharmacodynamic marker lysine hyperacetylation with clinical outcome....

2011-11-09 10:12:25

Method can be implemented into routine clinical practice, bringing effective personalized medicine a step closer Researchers in the United States have shown, for the first time, that it is possible to screen cancer patients for a broad range of cancer-causing genetic mutations as part of normal clinical practice. By identifying patients' individual genotypes within a relatively short time frame, doctors are able to target tumors with the most appropriate therapy. The study, which is...

2011-11-02 07:58:00

WALTHAM, Mass., Nov. 2, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that pharmacodynamic analysis in a subset of patients from ENCORE 301, a randomized phase 2 study of exemestane with and without entinostat in advanced breast cancer patients, will be presented in an oral session at the American Association for Cancer Research (AACR) Molecular Targets and Cancer Therapeutics Conference. The positive data was from...

2011-10-20 11:57:00

AUSTIN, Texas, Oct. 20, 2011 /PRNewswire/ -- Genprex, Inc. announced today that it will be presenting at the upcoming BIO Investor Forum, to be held in San Francisco. Greg Heinlein, Chief Operating and Financial Officer, is scheduled to present at the 10th annual BIO Investor Forum, on October 25 starting at 11 a.m. PDT in The Palace Hotel. A copy of the presentation slides will be made available on the company's website under the News & Media section on the day of the presentation....

2011-10-18 19:30:00

AUSTIN, Texas, Oct. 18, 2011 /PRNewswire/ -- A new patent covering tumor suppression technologies, including the company's lead product candidate Oncoprex(TM), was recently awarded to The University of Texas System by the Japan Patent Office. Patent number 4813746 pertains to the discovery that chromosome 3p21.3 genes act as cancer suppressors. The family of tumor suppressors include TUSC2, also known as FUS1, the anti-cancer agent in Oncoprex therapy which is undergoing clinical...

2011-10-14 16:30:00

BROOMFIELD, Colo., Oct. 14, 2011 /PRNewswire/ -- Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent®) and erlotinib (Tarceva®), by survival outcomes. Patients who tested VeriStrat Good had significantly longer progression free...

2011-10-05 10:00:00

PORTSMOUTH, N.H., Oct. 5, 2011 /PRNewswire/ -- Novocure, a commercial stage private oncology company, announced today that Gabriel Leung has joined its board of directors. Mr. Leung will serve as vice chairman of the board of directors and chairman of the company's global commercialization team. Mr. Leung retired as executive vice president of OSI Pharmaceuticals and the President of OSI's Pharmaceuticals Business following the Astellas Pharma Inc. acquisition of OSI in 2010. Mr....